Pharmacokinetics, bioavailability, & bioequivalence Original research| Volume 33, ISSUE 6, P754-765, June 2011

Effects of Food Intake on the Pharmacokinetic Properties of Dalcetrapib: Findings From Three Phase I, Single-Dose Crossover Studies in Healthy Volunteers



      Preclinical studies have reported that the relative bioavailability of dalcetrapib, a modulator of cholesteryl ester transfer protein (CETP) inhibitor activity, was ∼60% higher when administered in the fed state compared with the fasting state.


      This article reports on 3 studies conducted to assess the effects of food intake, timing of administration with respect to meals, and meal size and content on the relative bioavailability of dalcetrapib in healthy male subjects.


      Three Phase I studies were performed in healthy subjects: (1) a 2-period crossover study of a single dose of dalcetrapib 900 mg administered in the fed and fasting states (fed versus fasting study [1999]); (2) a 3-period crossover study of a single dose of dalcetrapib 600 mg administered after a light morning meal, a standard evening meal, and a light evening meal (meal timing/size study [2005]); and (3) a 4-period crossover study of a single dose of dalcetrapib 600 mg administered 30 minutes after a high-fat meal or a standard evening meal, and 30 minutes before or 3 hours after the latter (high-fat meal study [2007]). Blood samples for pharmacokinetic analyses (AUC0–36 or AUC0–∞, Cmax) were collected up to 36, 144, and 96 hours after study drug administration in the fed versus fasting, meal timing/size, and high-fat meal studies, respectively. CETP activity was measured using a radioisotopic method in the fed versus fasting study and a fluorometric method in the meal timing/size and high-fat meal studies. Tolerability was assessed using monitoring of adverse events, laboratory parameters, vital signs, and ECG.


      Six men were enrolled in the fed versus fasting study (mean age, 37 years; mean body mass index [BMI], 23.6 kg/m2). Dalcetrapib exposure was increased by 64% (AUC0–36) and 126% (Cmax) after administration in the fed state. Eighteen men were enrolled in the analysis of the effects of meal timing and size on the properties of dalcetrapib (mean age, 30.5 years; mean BMI, 25.1 kg/m2). When dalcetrapib was administered after a light morning or a light evening meal, comparable values were found for mean dalcetrapib AUC0–∞ (7400 and 7860 ng · h/mL, respectively) and Cmax (589 and 552 ng/mL), whereas administration after a standard evening meal was associated with increased AUC0–∞ (14.3%–14.7%) and Cmax (25.5%–35.3%). Forty-nine men were included in the analysis in the high-fat meal study (mean age, 32.3 years; mean BMI, 23.9 kg/m2). Compared with administration after a standard evening meal, administration after a high-fat evening meal was associated with increased AUC0–∞ (34.9%) and Cmax (43.7%). Between-treatment differences in exposure within each study also were reflected in apparent differences in CETP activity. All treatments were generally well tolerated.


      Dalcetrapib exposure was increased in the fed state and, to a lesser extent, was dependent on the size and fat content of the meal. Exposure was independent of dosing time. Dalcetrapib was generally well tolerated.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Barter P.
        • Gotto A.M.
        • LaRosa J.C.
        • et al.
        • Treating to New Targets (TNT) Investigators
        HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.
        N Engl J Med. 2007; 357: 1301-1310
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • et al.
        • Treating to New Targets (TNT) Investigators
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Pedersen T.R.
        • Faergeman O.
        • Kastelein J.J.
        • et al.
        • Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group
        High-dose atorvastatin versus usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial.
        JAMA. 2005; 294: 2437-2445
        • Gordon T.
        • Castelli W.P.
        • Hjortland M.C.
        • et al.
        High density lipoprotein as a protective factor against coronary heart disease.
        Am J Med. 1977; 62: 707-714
        • Assmann G.
        • Schulte H.
        • von Eckardstein A.
        • Huang Y.
        High-density lipoprotein cholesterol as a predictor of coronary heart disease risk.
        Atherosclerosis. 1996; 124: S11-S20
        • Singh I.M.
        • Shishehbor M.H.
        • Ansell B.J.
        High-density lipoprotein as a therapeutic target: a systematic review.
        JAMA. 2007; 298: 786-798
        • Inazu A.
        • Brown M.L.
        • Hesler C.B.
        • et al.
        Increased high-density lipoprotein levels caused by a common cholesteryl-ester transfer protein gene mutation.
        N Engl J Med. 1990; 323: 1234-1238
        • Ordovas J.M.
        • Cupples L.A.
        • Corella D.
        • et al.
        Association of cholesteryl ester transfer protein—TaqIB polymorphism with variations in lipoprotein subclasses and coronary heart disease risk.
        Arterioscler Thromb Vasc Biol. 2000; 20: 1323-1329
        • Brousseau M.E.
        • O'Connor Jr, J.J.
        • Ordovas J.M.
        • et al.
        Cholesteryl ester transfer protein Taq1 B2B2 genotype is associated with higher HDL cholesterol levels and lower risk of coronary heart disease end points in men with HDL deficiency.
        Arterioscler Thromb Vasc Biol. 2002; 22: 1148-1154
        • Boekholdt S.M.
        • Kuivenhoven J.A.
        • Wareham N.J.
        • et al.
        Plasma levels of cholesteryl ester transfer protein and the risk of future coronary artery disease in apparently healthy men and women: the prospective EPIC (European Prospective Investigation into Cancer and nutrition)-Norfolk population study.
        Circulation. 2004; 110: 1418-1423
        • Klerkx A.H.
        • de Grooth G.J.
        • Zwinderman A.H.
        • et al.
        Cholesteryl ester transfer protein concentration is associated with progression of atherosclerosis and response to pravastatin in men with coronary artery disease (REGRESS).
        Eur J Clin Invest. 2004; 34: 21-28
        • Barter P.J.
        • Kastelein J.J.
        Targeting cholesteryl ester transfer protein for the prevention and management of cardiovascular disease.
        J Am Coll Cardiol. 2006; 47: 492-499
        • de Grooth G.J.
        • Kuivenhoven J.A.
        • Stalenhoef A.F.
        • et al.
        Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study.
        Circulation. 2002; 105: 2159-2165
        • Kuivenhoven J.A.
        • de Grooth G.J.
        • Kawamura H.
        • et al.
        Effectiveness of inhibition of cholesteryl ester transfer protein by JTT-705 in combination with pravastatin in type II dyslipidemia.
        Am J Cardiol. 2005; 95: 1085-1088
        • Stein E.A.
        • Stroes E.S.
        • Steiner G.
        • et al.
        Safety and tolerability of dalcetrapib.
        Am J Cardiol. 2009; 104: 82-91
        • Stein E.A.
        • Roth E.M.
        • Rhyne J.M.
        • et al.
        Safety and tolerability of dalcetrapib (RO4607381/JTT-705): results from a 48-week trial.
        Eur Heart J. 2010; 31: 480-488
        • Derks M.
        • Fowler S.
        • Kuhlmann O.
        In vitro and in vivo assessment of the effect of dalcetrapib on a panel of CYP substrates.
        Curr Med Res Opin. 2009; 25: 891-902
        • Derks M.
        • Abt M.
        • Parr G.
        • et al.
        No clinically relevant drug–drug interactions when dalcetrapib is coadministered with atorvastatin.
        Expert Opin Investig Drugs. 2010; 19: 1135-1145
        • Derks M.
        • Abt M.
        • Phelan M.
        • et al.
        Coadministration of dalcetrapib with pravastatin, rosuvastatin, or simvastatin: no clinically relevant drug–drug interactions.
        J Clin Pharmacol. 2010; 50: 1188-1201
        • Fleisher D.
        • Li C.
        • Zhou Y.
        • Pao L.-H.
        • Karim A.
        Drug, meal and formulation interactions influencing drug absorption after oral administration.
        Clin. Pharmacokinet. 1999; 36: 233-254
        • Dale O.
        • Salo M.
        The Helsinki Declaration, research guidelines and regulations: present and future editorial aspects.
        Acta Anaesthesiol Scand. 1996; 40: 771-772
      1. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) adopts Consolidated Guideline on Good Clinical Practice in the Conduct of Clinical Trials on Medicinal Products for Human Use.
        Int Dig Health Legis. 1997; 48: 231-234
        • Kuhlmann O.
        • Heinig K.
        Dalcetrapib pharmacokinetics and metabolism in the Cynomolgus monkey.
        Xenobiotica. 2011; 41: 430-436
        • Kato H.
        • Nakanishi T.
        • Arai H.
        • et al.
        Purification, microheterogeneity, and stability of human lipid transfer protein.
        J Biol Chem. 1989; 264: 4082-4087
        • Pacific Biomarkers Inc
        CETP- Activity (Cholesteryl Ester Transfer Protein Activity).
        (Accessed May 23, 2011)
        • Gibaldi M.
        • Perrier D.
        Noncompartmental analysis based on statistical moment theory.
        in: Pharmacokinetics. Marcel Dekker, New York, NY1982
        • Hourcade-Potelleret F.
        Preliminary population PK-PD of dalcetrapib: an agent targeting CETP to raise HDL-C and prevent cardiovascular morbidity and mortality.
        (Accessed June 9, 2010)
        • Krishna B.
        • Bergman A.J.
        • Jin B.
        • et al.
        Multiple-dose pharmacodynamics and pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects.
        Clin Pharmacol Ther. 2008; 84: 679-683
        • Schwartz G.G.
        • Olsson A.G.
        • Ballantyne C.M.
        • et al.
        • dal-OUTCOMES Committees and Investigators
        Rationale and design of the dal-OUTCOMES trial: efficacy and safety of dalcetrapib in patients with recent acute coronary syndrome.
        Am Heart J. 2009; 158: 896-901
        • Derks M.
        • Abt M.
        • Mwangi A.
        • Meneses-Lorente G.
        Lack of effect of dalcetrapib on QT interval in healthy subjects following multiple dosing.
        Eur J Clin Pharmacol. 2010; 66: 775-783